Related Experiment Video

Updated: Mar 25, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Etirinotecan pegol for the treatment of breast cancer

Elena López-Miranda1, Javier Cortés1,2

  • 1a Department of Medical Oncology , Ramon y Cajal University Hospital , Madrid , Spain.

Expert Opinion on Pharmacotherapy
|February 17, 2016
PubMed
Abstract

Insights

Etirinotecan pegol shows promise for advanced breast cancer treatment. This novel topoisomerase I inhibitor offers anti-tumor activity with improved tolerability, addressing resistance challenges.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Advanced breast cancer remains largely incurable, necessitating novel therapeutic strategies.
  • Current treatments face limitations due to cross-resistance and overlapping toxicities.
  • There is a significant unmet need for innovative agents in refractory metastatic breast cancer.

Purpose of the Study:

  • To review etirinotecan pegol as a potential new agent for refractory metastatic breast cancer.
  • To examine the pharmacology, safety, and efficacy of etirinotecan pegol.
  • To assess its potential to overcome treatment resistance and toxicity issues.

Main Methods:

  • Review of preclinical and clinical trial data for etirinotecan pegol.
  • Examination of etirinotecan pegol's novel design as a long-acting polymer conjugate of irinotecan.
  • Analysis of its mechanism as a topoisomerase I inhibitor concentrating in tumors.

Main Results:

  • Etirinotecan pegol demonstrated promising anti-tumor activity in Phase II trials for advanced breast cancer.
  • Activity was maintained in poor prognostic subgroups.
  • Low rates of neutropenia and neuropathy were observed, suggesting improved tolerability.

Conclusions:

  • Etirinotecan pegol exhibits significant anti-tumor activity and improved tolerability in patients with refractory metastatic breast cancer.
  • As a novel topoisomerase I inhibitor, it holds therapeutic potential for advanced disease.
  • It offers a new approach to address resistance challenges in breast cancer treatment.
Keywords:
Advanced or metastatic breast cancerChemotherapy-resistantEtirinotecan pegolPolymer-based medicine

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.6K
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

6.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K